Sight Sciences, Inc. (SGHT)
| Previous close | 6.32 |
| Open | 6.30 |
| Bid | 6.31 x 200 |
| Ask | 6.52 x 200 |
| Day's range | 6.30 - 6.55 |
| 52-week range | 1.04 - 9.31 |
| Volume | |
| Avg. volume | 155,856 |
| Market cap | 319.435M |
| Beta (5Y monthly) | 2.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.10 |
Simply Wall St.One Sight Sciences Insider Raised Stake By 34% In Previous Year
Insiders were net buyers of Sight Sciences, Inc.'s ( NASDAQ:SGHT ) stock during the past year. That is, insiders bought...
GlobeNewswireSight Sciences Announces the Release of its First Sustainability Report
The Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiativesMENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company’s
- GlobeNewswire
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve.MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional techn
